Reference:
Faksova, K., Walsh, D., Jiang, Y., Griffin, J., Phillips, A., Gentile, A., Kwong, J.C., Macartney, K., Naus, M., Grange, Z., Escolano, S., Sepulveda, G., Shetty, A., Pillsbury, A., Sullivan, C., Naveed, Z., Janjua, N.Z., Giglio, N., Perälä, J., Nasreen, S., Gidding, H., Hovi, P., Vo, T., Cui, F., Deng, L., Cullen, L., Artama, M., Lu, H., Clothier, H.J., Batty, K., Paynter, J., Petousis-Harris, H., Buttery, J., Black, S., & Hviid, A. (2024). COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. https://doi.org/10.1016/j.vaccine.2024.01.100
Summary:
This multinational study assessed the risk of adverse events of special interest (AESI) following COVID-19 vaccination, involving over 99 million vaccinated individuals across ten sites in eight countries. The research focused on comparing observed rates of 13 selected AESI against expected rates derived from pre-vaccination healthcare data. Significant findings included increased observed rates for Guillain-Barré syndrome and cerebral venous sinus thrombosis post-ChAdOx1 vaccination, as well as higher risks of myocarditis and pericarditis following mRNA vaccinations. The study confirms previously acknowledged safety signals and highlights the need for continued monitoring of rare adverse events associated with COVID-19 vaccines.